Related Experiment Video

Updated: Apr 20, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.2K

Recent advances of p53-MDM2 small molecule inhibitors (2011-present)

Peng-Cheng Lv, Juan Sun, Hai-Liang Zhu1

  • 1State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, People's Republic of China. zhuhl@nju.edu.cn.

Current Medicinal Chemistry
|December 3, 2014
PubMed

Insights

This review focuses on small-molecule inhibitors targeting the p53-MDM2 interaction, a key pathway in cancer. It analyzes structure-activity relationships of these potential cancer therapeutics developed since 2011.

Area of Science:

  • Molecular Biology
  • Oncology
  • Medicinal Chemistry

Background:

  • The p53 protein is crucial for cellular processes like DNA repair and apoptosis.
  • MDM2 inhibits p53 activity, making the p53-MDM2 interaction a target for cancer therapy.
  • Small-molecule inhibitors of p53-MDM2 are being developed as anti-cancer agents.

Purpose of the Study:

  • To review the development of p53-MDM2 inhibitors from 2011 to the present.
  • To analyze the structure-activity relationships of these inhibitors.
  • To highlight recent advances in small-molecule inhibitor design for cancer treatment.

Main Methods:

  • Literature review of studies published from 2011 to the present.
  • Analysis of structure-activity relationships (SAR) of p53-MDM2 inhibitors.
  • Focus on compounds that have advanced into clinical trials.

Main Results:

  • Several small-molecule inhibitors targeting the p53-MDM2 interaction have been developed.
  • Advances in inhibitor design have led to compounds entering clinical trials.
  • Structure-activity relationship analysis provides insights into optimizing inhibitor efficacy.

Conclusions:

  • Inhibitors of the p53-MDM2 interaction represent a promising therapeutic strategy for cancer.
  • Continued research into SAR is vital for developing more effective cancer treatments.
  • The review consolidates recent findings to guide future drug development.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
3.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K